Study Suggests Clinicians Use Fully Covered Metal Stents in Patients with Pancreatic Adenocarcinoma

Share
  • Twitter
  • Facebook
  • email
  • StumbleUpon
  • Delicious
  • Google Reader
  • LinkedIn
  • Google Bookmarks

    Timothy B. Gardner, MD, MS

    Timothy B. Gardner, MD, MS

    Oral 49 Cost Effectiveness and Clinical Efficacy of Plastic vs Self-Expandable Metal Stents for Management of Biliary Obstruction due to Pancreatic Adenocarcinoma in Patients Undergoing Neoadjuvant Therapy

    Author Insight from Timothy B. Gardner, MD, MS, Dartmouth-Hitchcock Medical Center

    timothy.b.gardner@hitchcock.org

    What’s new here and important for clinicians?

    This is the first study that demonstrates that fully covered metal stents are cost effective in the treatment of patients undergoing neoadjuvant therapy for pancreatic cancer. Previously, it was known that metal stents were less likely to occlude, but now we know that because metal stents prevent occlusion and the costs associated with that occlusion, the initial up front cost is offset by their prevention of subsequent complications and associated costs. This is the first time that this has been demonstrated in a randomized controlled trial.

    What do patients need to know?

    Clinicians should be placing fully covered metal stents when they treating patients who are diagnosed with pancreatic cancer because of their clinical efficacy and cost effectiveness.

    Read the abstract

    Author Contact Timothy B. Gardner, MD, MS Dartmouth-Hitchcock Medical Center

    timothy.b.gardner@hitchcock.org


    Media Interview Requests:

    To arrange an interview with any ACG experts or abstract authors please contact Jacqueline Gaulin of ACG via email jgaulin@gi.org or by phone at 301-263-9000.

    Share
    • Twitter
    • Facebook
    • email
    • StumbleUpon
    • Delicious
    • Google Reader
    • LinkedIn
    • Google Bookmarks